BR9610050A - Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo - Google Patents

Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo

Info

Publication number
BR9610050A
BR9610050A BR9610050-8A BR9610050A BR9610050A BR 9610050 A BR9610050 A BR 9610050A BR 9610050 A BR9610050 A BR 9610050A BR 9610050 A BR9610050 A BR 9610050A
Authority
BR
Brazil
Prior art keywords
enzyme
host
conjugate
vector
compounds
Prior art date
Application number
BR9610050-8A
Other languages
English (en)
Inventor
Anthony Michael Slater
David Charles Blakey
Jonh Frederick Hennam
David Huw Davies
Peter Robert Marsham
Robert Ian Dowell
Laurent Francois And Hennequin
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Priority claimed from GBGB9611019.2A external-priority patent/GB9611019D0/en
Priority claimed from GBGB9612295.7A external-priority patent/GB9612295D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of BR9610050A publication Critical patent/BR9610050A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"CONJUGADO, SISTEMA DE DOIS COMPONENTES COMBINADOS DESTINADOS A USO EM UM HOSPEDEIRO, COMPOSTOS OU UM SAL DESTES FARMACEUTICAMENTE ACEITáVEL, ENZIMA, SEQUêNCIA DE POLINUCLEOTìDEOS E DE NUCLEOTìDEOS, VETOR, CéLULA HOSPEDEIRA, PROCESSOS DE PRODUçãO DE UMA ENZIMA E DE UM CONJUGADO E DE TRATAMENTO DE CéLULAS NEOPLáSTICAS EM UM HOSPEDEIRO, COMPOSIçãO FARMACêUTICA E PLASMìDEO". Os sistemas de Terapia de Pró-medicamentos de Enzimas dirigidas a Anticorpos(ADEPT) para uso em câncer com base em carboxipeptidase B (CPB) enzimas transformada. Os conjugados enzimáticos para ADEPT são substancialmente não imunogênicos em seres humanos, compreendendo uma porção de alvejamento (por exemplo um anticorpo) capaz de ligação com um antígeno associado a tumor, a porção alvo sendo ligada a uma forma transfomada de uma enzima CPB capaz de converter um pró-medicamento em um medicamento anti-neoplástico, em que o pró-medicamento não é significativamente convertível em medicamento anti-neoplástico em seres humanos pela enzima natural não transformada. Um mutante enzimático preferido é a CPB pancreática humana, compreendendo um resíduo Lys ou Arg na posição 253. Pró-medicamentos de mostarda adequados são apresentados no relatório descritivo.
BR9610050-8A 1995-08-16 1996-08-13 Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo BR9610050A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GBGB9611019.2A GB9611019D0 (en) 1996-05-25 1996-05-25 Chemical compounds
GBGB9612295.7A GB9612295D0 (en) 1996-06-12 1996-06-12 Chemical compounds
PCT/GB1996/001975 WO1997007769A2 (en) 1995-08-16 1996-08-13 Chemical compounds

Publications (1)

Publication Number Publication Date
BR9610050A true BR9610050A (pt) 1999-10-13

Family

ID=27267862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610050-8A BR9610050A (pt) 1995-08-16 1996-08-13 Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo

Country Status (19)

Country Link
US (1) US6436691B1 (pt)
EP (1) EP0844885A2 (pt)
JP (1) JPH11511970A (pt)
KR (1) KR19990036383A (pt)
CN (1) CN1193278A (pt)
AU (1) AU707689B2 (pt)
BR (1) BR9610050A (pt)
CA (1) CA2227040A1 (pt)
CZ (1) CZ43098A3 (pt)
GB (1) GB2317387B (pt)
HU (1) HUP9900062A3 (pt)
IL (1) IL123271A0 (pt)
MX (1) MX9800967A (pt)
NO (1) NO980630L (pt)
NZ (1) NZ315713A (pt)
PL (1) PL325017A1 (pt)
SK (1) SK19498A3 (pt)
TR (1) TR199800233T1 (pt)
WO (1) WO1997007769A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707689B2 (en) 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
KR20020073127A (ko) * 1999-09-17 2002-09-19 겐자임 트랜스제닉스 코포레이션 형질전환에 의하여 생성된 융합 단백질
DK1794294T3 (da) * 2004-09-27 2011-10-31 Sanofi Aventis Deutschland Rekombinant carboxypeptidase B
WO2010009074A2 (en) * 2008-07-14 2010-01-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for predicting and detecting tumor metastasis
ES2595364T3 (es) * 2008-10-07 2016-12-29 The Regents Of The University Of California Producción de proteínas NELL recombinantes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
HU190129B (en) * 1983-07-11 1986-08-28 Reanal Finomvegyszergyar,Hu Process for the isolation of carboxypeptidase b enzyme from mammal pancreas
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
ATE123414T1 (de) 1989-01-23 1995-06-15 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0625205A1 (en) 1992-01-30 1994-11-23 Genzyme Limited Chiral synthesis with modified enzymes
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity
JP3805365B2 (ja) * 1994-12-23 2006-08-02 シンジェンタ リミテッド 化合物
IL116696A (en) * 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
AU707689B2 (en) 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
GB2317387B (en) 1999-08-18
GB2317387A (en) 1998-03-25
NO980630D0 (no) 1998-02-13
CZ43098A3 (cs) 1998-05-13
TR199800233T1 (xx) 1998-06-22
GB9726893D0 (en) 1998-02-18
NZ315713A (en) 1999-08-30
CN1193278A (zh) 1998-09-16
AU707689B2 (en) 1999-07-15
US6436691B1 (en) 2002-08-20
HUP9900062A2 (hu) 1999-04-28
SK19498A3 (en) 1998-09-09
JPH11511970A (ja) 1999-10-19
EP0844885A2 (en) 1998-06-03
IL123271A0 (en) 1998-09-24
PL325017A1 (en) 1998-07-06
AU6747696A (en) 1997-03-19
MX9800967A (es) 1998-11-29
CA2227040A1 (en) 1997-03-06
WO1997007769A3 (en) 1997-07-10
HUP9900062A3 (en) 1999-11-29
NO980630L (no) 1998-04-07
WO1997007769A2 (en) 1997-03-06
KR19990036383A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
Walther et al. Prodrugs in medicinal chemistry and enzyme prodrug therapies
Walsh et al. A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates
Senter et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates
ES2736505T3 (es) Nuevo conjugado estable de anticuerpo-fármaco, método de preparación y uso del mismo
Swenson et al. Amino acid sequence of the tryptic peptide containing the alkylamine-reactive site from human alpha 2-macroglobulin. Identification of gamma-glutamylmethylamide.
WO1996034969A3 (en) Gene therapy using replication competent targeted adenoviral vectors
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
ES2123662T3 (es) Derivados de mostaza nitrogenada enlazada a aminoacidos y su uso como profarmacos en el tratamiento de tumores.
WO2007008463A3 (en) Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
AU3057297A (en) Targeted combination immunotherapy of cancer
BR9510490A (pt) Sistema combinado de dois componentes designado para uso em um hospedeiro ribonucleotídeo de mostarda composição farmacêutica meio componente enzima mutante processo de controle do crescimento de células neoplásticas em um hospedeiro plasmídeo sequência de polinucleotídeo vetor e célula
GB2286593A (en) Virus with modified binding moiety specific for the target cells
BR9808769A (pt) Construção de gene, uso de uma construção de gene, sistema de dois componentes emparelhados, designado para o uso em um hospedeiro mamìfero, e, processo para transferência de um medicamento citotóxico para um sìtio
BR9610050A (pt) Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
CY1109881T1 (el) Νεοαγγειακα-συγκεκριμενα πεπτιδια
Satyam Design and synthesis of releasable folate–drug conjugates using a novel heterobifunctional disulfide-containing linker
Eccles et al. Regression of Established Breast Carcinoma Xenografts with Antibody-directed Enzyme Prodrug Therapy against c-erb B2 p185
Fiume et al. Galactosylated poly (L-lysine) as a hepatotropic carrier of 9-β-D-arabinofuranosyladenine 5'-monophosphate
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
BR0015597A (pt) Uso de anticorpos como vacinas
WO1999063945A3 (en) Vaccination strategy to prevent and treat cancers
NO20011817D0 (no) Ionebytte-tumormålsöking (IETT)
WO2000047611A3 (en) Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
WO2022172083A3 (en) Targeted nucleic acid therapy for hepatitis b

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law